KRAS and neoplasm: Genetic analysis using Luminex 100/200 technology (Luminex Corporation, Austin, TX, USA) on a formalin-fixed, paraffin-embedded tumor sample from the surgical specimen revealed a KRAS mutation (p.G12V).